SIETES :: 92718 citas

Resultados de la búsqueda por CLOPIDOGREL REFINAR BÚSQUEDA

1.

Anónimo. Troubles rétiniens d'origine médicamenteuse. Prescrire 2019;39:19-25. [Ref.ID 103005]

2.

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

3.

Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, for the Clinical Research Collaboration Neurological Emergencies Treatment Trials Network and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:19 de julio. [Ref.ID 102746]

4.

Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]

5.

Dekkers T, Lafeber M, Kramers C. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102523]

6.

Wang X, Karnieg T. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102522]

7.

Uyhazi KE, Miano T, Pan W, VanderBeek BL. Association of novel oral antithrombotics with the risk of intraocular bleeding. Jama Ophthalmol 2017:14 de diciembre. [Ref.ID 102190]

8.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

9.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

10.

Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med 2017;377:1580-2. [Ref.ID 102100]

11.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, ten Berg JM, Steg PG, Hohnloser SH, for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-24. [Ref.ID 102099]

12.

Anónimo. Clopidogrel: augmentation des effets indésirables du paclitaxel. Prescrire 2017;37:344-5. [Ref.ID 101651]

13.

Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S-J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. The American Journal of Gastroenterology 2017;112:1084-93. [Ref.ID 101543]

14.

Yasmina A, de Boer A, Deneer VHM, Souverein PC, Klungel OH. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol 2017;83:632-41. [Ref.ID 101464]

15.

Jolly SS, Natarajan MK. Atrial fibrillation and PCI - Do we still need aspirin?. N Engl J Med 2016;373:2490-2. [Ref.ID 101034]

16.

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;373:2423-34. [Ref.ID 101032]

17.

Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]

18.

Anónimo. AstraZeneca says Brilinta failed to show PAD benefit over generic blood thinner. DIA Daily 2016:5. [Ref.ID 100778]

19.

Hankey GJ. The benefits of aspirin in early secondary stroke prevention. N Engl J Med 2016;388:312-4. [Ref.ID 100643]

20.

Johnston SC, Amarenco P, Albers GW, Denison H, Easton D, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43. [Ref.ID 100628]